Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Sep 29 · below the Ichimoku cloud · RSI 41 · MACD below its signal
| 97.97 | 52-week high | +52.48% |
| 77.67 | Previous month high | +20.89% |
| 74.45 | R3 (classic) | +15.88% |
| 73.11 | Previous week high | +13.79% |
| 71.78 | R2 (classic) | +11.71% |
| 69.10 | Previous day high | +7.55% |
| 68.01 | R1 (classic) | +5.86% |
| 65.34 | Pivot | +1.69% |
| 64.25 | Price now | |
| 62.66 | Previous day low | −2.47% |
| 62.66 | Previous week low | −2.47% |
| 61.57 | S1 (classic) | −4.17% |
| 58.90 | S2 (classic) | −8.33% |
| 58.30 | Previous month low | −9.26% |
| 55.13 | S3 (classic) | −14.19% |
| 28.81 | 52-week low | −55.16% |
None of the 29 investors followed here reported a position in SLGL in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SLGL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 65.94 - 66.80 per share. | 3.1K | $207.40K |
| Sep 8, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 68.70 - 69.52 per share. | 10K | $687.16K |
| Sep 1, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 68.95 - 69.52 per share. | 1.7K | $116.49K |
| Aug 30, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 68.24 - 71.40 per share. | 40.3K | $2.79M |
| Aug 11, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 71.50 per share. | 951 | $68.00K |
| Jul 13, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 73.43 - 73.89 per share. | 1.7K | $124.82K |
| Jul 9, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 73.69 - 73.95 per share. | 529 | $39.04K |
| Jul 1, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 71.97 - 71.99 per share. | 1.7K | $123.22K |
| May 19, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 64.43 per share. | 1.6K | $100.71K |
| May 12, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 66.87 - 67.98 per share. | 3.4K | $231.50K |
| Mar 23, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 72.00 per share. | 39.7K | $2.86M |
| Feb 12, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 63.00 per share. | 291 | $18.33K |
| Feb 1, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 58.00 per share. | 100 | $5.80K |
| Feb 1, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 58.00 per share. | 100 | $5.80K |
| Jan 26, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 57.05 per share. | 100 | $5.71K |
| Jan 22, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 55.98 - 56.57 per share. | 3.3K | $187.36K |
| Jan 4, 2026 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 41.92 - 42.98 per share. | 2.6K | $108.86K |
| Dec 30, 2025 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 41.85 - 41.99 per share. | 66.3K | $2.78M |
| Dec 25, 2025 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 41.15 - 41.68 per share. | 2.9K | $120.53K |
| Dec 16, 2025 | Opaleye Management, Inc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 40.37 per share. | 2.7K | $110.41K |
TimeframesUp on the monthly, down on the hourly and daily, mixed on the weekly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
over a rising 21 EMA, 21 over 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 52.4 | 42.8 | -13.6 | -6.5 | -0.2 | 0.4 | 10.9 | -16.0 | 7.5 | -13.5 | +52.5% | ||
| 2025 | -17.7 | -12.4 | -22.4 | 46.2 | -5.1 | 2.6 | 70.3 | 80.9 | 27.9 | 18.4 | 22.9 | -0.6 | +353.1% |
| 2024 | 26.7 | -20.0 | -12.5 | -27.2 | 12.2 | 11.2 | -52.2 | 64.5 | -2.7 | -27.9 | 14.5 | 65.8 | −15.8% |
| 2023 | 12.3 | -14.7 | -11.1 | -7.5 | 0.3 | -16.9 | 24.2 | -29.7 | -37.5 | -20.2 | 0.4 | -15.3 | −75.8% |
| 2022 | -5.8 | 5.5 | 0.4 | -3.8 | -17.2 | -30.3 | 36.8 | 8.6 | -17.6 | -1.3 | -4.5 | -3.6 | −38.4% |
| 2021 | -0.6 | -8.5 | 39.1 | -11.6 | -5.6 | 19.8 | -9.3 | -12.6 | 1.8 | -10.0 | -16.1 | -2.0 | −24.4% |
| 2020 | -25.2 | -20.8 | -30.5 | 16.9 | -6.4 | 16.0 | -18.2 | 7.8 | -8.2 | 11.2 | 11.8 | 8.8 | −42.9% |
| 2019 | -0.5 | 16.9 | -3.3 | 6.9 | 16.0 | 8.4 | 11.9 | -18.1 | 7.7 | -11.0 | 3.6 | 106.9 | +184.9% |
| 2018 | -4.5 | -19.0 | 16.3 | -20.4 | -9.3 | -10.1 | 19.2 | -10.8 | -0.3 | -9.7 | −44.2% |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Buy / hold / sell counts